No profile data available.
Immunocore Holdings plc (IMCR) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Abingdon, United Kingdom, with about 524 full-time employees.
It reported revenue of $310.20 million for fiscal year 2024, up 24.4% from fiscal year 2023, and net income of -$51.09 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $103.69 million, up 29.2% from a year before. United States was its largest region in fiscal year 2025, with 64% of revenue. Its market capitalization was $1.51 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Immunocore Holdings reported $310.20 million in revenue for fiscal year 2024, up 24.4% from $249.43 million in fiscal year 2023. In Q3 2025 revenue was $103.69 million.
United States: 64% of revenue by region in fiscal year 2025, followed by Europe (33%).
$1.51 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Xencor, Inc. (XNCR), ANI Pharmaceuticals, Inc. (ANIP), Ocular Therapeutix, Inc. (OCUL), Nektar Therapeutics (NKTR).